Navigation Links
Cellectis Publishes Its Financial Statement for the First Half of 2010

PARIS, Oct. 15 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, today published its consolidated financial statement for the half-year ending June 30, 2010: revenues increased 25% over H1 2009, expenditure increased 50% and the company ended the period with euro 38 million in cash reserves.

During the first half of 2010, Cellectis entered into a number of important new agreements (with BASF Plant Science, Boehringer Ingelheim), published data in a peer-reviewed journal on the therapeutic potential of meganucleases in Duchenne muscular dystrophy and launched Cellectis plant sciences. Cellectis was also granted the INPI National Innovation Award for its intellectual property strategy. In addition, Cellectis' research and production tools subsidiary, Cellectis bioresearch, entered into a development and commercial manufacturing agreement with Lonza that establishes a presence for Cellectis in the bioproduction market.

"The figures for this half year reflect our growth strategy," said Andre Choulika, CEO at Cellectis. "Cellectis' staff has doubled in a year and comprises 130 people today, in all entities, compared to 65 in July 2009. This has allowed us to strengthen our position, in all aspects of our business, with highly competent and committed people."

"The capital increase that was made in October 2009 allows us to finance this rapid growth and support our ambitious external growth strategy," added Marc Le Bozec, CFO at Cellectis.

The slide show presenting the half-year results in details is available on Simplified Income Statement – Financial items are presented according to IFRSFigures in thousands of euros

first 6 months2009
first  6 monthsSales

6 2505 020Other revenue

6336Total revenue6 3135 056Consumables

(1 231)(901)Wages & Salaries

(4 502)(2 908)Other operating expenses

(9 276)(6 752)Tax

(168)(193)Depreciation & Amortization

(139)(221)Total operating expenses(15 316)(10 975)Current operating income/loss(9 003)(5 919)Other non-current income and expenses

4661Operating income (loss)(8 957)(5 858)Financial income

241282Financial expenses

(17)(1)Cost of financing, net225281Income tax

5 2402 810Net operating income (loss)(3 492)(2 767)About CellectisCellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over euro 70 million in funding since inception.

More information at

Follow Cellectis on Twitter at

DisclaimerThis press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
2. Cellectis Bioresearch and Cedarlane Join Forces for the Distribution of cGPS® and cGPS® Custom Kits in Canada
3. Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India
4. Cellectis bioresearch Announces Establishment of Subsidiary in the US
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
8. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
9. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
(Date:11/24/2015)... 2015  Thanks to a donor with a personal ... Center,s Sister Diane Grassilli Center for Women,s Health now ... San Francisco . Fred ... with a gift of $617,320 that allowed the Center ... Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) mammography ...
(Date:11/24/2015)... Nov. 24, 2015  Natera, Inc. (Nasdaq: ... genetic testing and the analysis of circulating ... present at the 27 th  Annual Piper ... 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of ... business activities and financial outlook. ...
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Charitable giving is at ... are made in the last five weeks of the year totalling over $358 billion ... 2012 to connect the nation’s charities with those individuals who want to “give back” ...
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... ... sizes, has launched their Black Friday sale a week early, offering 40% off ... to transform the intimate apparel industry through both mobile fit technology and the ...
(Date:11/24/2015)... Los Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... author explored the different restrictions and variables that determine which patients are or are ... are those patients that have a BMI over 40, are more than 100 pounds ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced that ... Clinical Trial Supply East Asia Conference, to be held at the InterContinental Seoul ...
(Date:11/24/2015)... ... November 24, 2015 , ... DMG Productions announced that they ... airing first quarter 2016 via Discovery Channel. Dates and show times TBA. , Aphria, ... is in the business of producing and supplying medical marijuana pursuant to the Marijuana ...
Breaking Medicine News(10 mins):